Trial: 202006109

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis

Phase

III

Principal Investigator

Stockerl-Goldstein, Keith

Disease Site

Bone Marrow Transplant; Kidney; Liver; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov